Supporting a Global Movement

Supporting a growing network of advocates fighting for HIV prevention and global health equity

We prioritize skills-sharing and knowledge-exchange among communities, advocates, civil society, researchers, donors, policy-makers and other stakeholders, and work to cultivate and sustain dynamic partnerships that set bold and innovative agendas for HIV prevention.

Global and national policymakers, funders and partners, and researchers use various strategies to guide decisions on policy, funding and program choices. Civil society often has uneven and incomplete access to this information and are therefore less able to engage and advocate for inclusive and people-centered research, programs, products, and policies for HIV prevention that are based on evidence. 

Together with our partners, AVAC supports and fortifies a robust network of bold and informed advocates and coalitions to advance inclusive, effective, people-centered policies and programs and we do this by: 

  • promoting informed decision making, evidence-based advocacy and awareness raising around timely issues in HIV prevention research and product development, as well as integration with other related areas of health equity; 
  • informing civil society of and equipping them with the latest scientific evidence, policy and funding decisions; 
  • conducting and supporting programs and trainings to support civil society in conducting successful advocacy campaigns;
  • hosting and supporting mentoring programs that prioritize skills and power sharing, North-South solidarity, and impact-oriented advocacy.

The Latest on Supporting a Global Movement

Article

Advocacy: Now more than ever

We are in a period of profound uncertainty, remarkable progress and tremendous concern—for the state of the world, for the state of global health and HIV, and for the specific work that AVAC and our partners do. We’ve seen incredible advances in biomedical prevention in 2024 with the introduction of the dapivirine vaginal ring (DVR) and injectable cabotegravir (CAB) for PrEP and the spectacular clinical trial results of injectable lenacapavir—the combination of which could transform lives if rolled out with speed, scale and equity.

Podcast

PxPulse: The Votes are In — What’s next for the US’ role in global health and HIV prevention

In the days ahead under a new US Presidential Administration, advocacy for choice, freedom, science, and rights will require intentional strategies to protect hard fought gains in HIV treatment and prevention. And there will be major implications for the global AIDS response.